AQR Capital Management LLC Grows Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL)

AQR Capital Management LLC lifted its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 145.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,219 shares of the biotechnology company’s stock after buying an additional 26,821 shares during the quarter. AQR Capital Management LLC owned approximately 0.05% of Anavex Life Sciences worth $191,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Fiduciary Alliance LLC purchased a new stake in shares of Anavex Life Sciences in the 1st quarter worth about $67,000. SG Americas Securities LLC purchased a new stake in Anavex Life Sciences during the 2nd quarter valued at about $57,000. EntryPoint Capital LLC grew its position in Anavex Life Sciences by 371.1% during the 1st quarter. EntryPoint Capital LLC now owns 20,007 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 15,760 shares during the last quarter. Virtu Financial LLC purchased a new stake in Anavex Life Sciences during the 4th quarter valued at about $202,000. Finally, Saxon Interests Inc. purchased a new stake in Anavex Life Sciences during the 1st quarter valued at about $136,000. 31.55% of the stock is owned by hedge funds and other institutional investors.

Anavex Life Sciences Stock Up 2.6 %

Shares of NASDAQ AVXL opened at $5.65 on Friday. The firm’s 50-day moving average price is $5.68 and its 200-day moving average price is $4.95. The company has a market cap of $478.23 million, a PE ratio of -11.30 and a beta of 0.61. Anavex Life Sciences Corp. has a 52-week low of $3.25 and a 52-week high of $10.45.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. During the same quarter in the previous year, the company posted ($0.14) EPS. As a group, equities research analysts anticipate that Anavex Life Sciences Corp. will post -0.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. EF Hutton Acquisition Co. I raised shares of Anavex Life Sciences to a “strong-buy” rating in a research report on Monday, July 22nd. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Anavex Life Sciences in a research report on Friday.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.